The DOI matches its Crossref record.
Structure-activity and structure-side-effect relationships for the quinolone antibacterials
Abstract
The fluoroquinolones represent a major class of antibacterials with great therapeutic potential. Over the years, several structure-activity and side-effect relationships have been developed, covering thousands of analogues, in an effort to improve overall antimicrobial efficacy while reducing undesirable side-effects. In this review, the various structural features of the quinolones which govern antibacterial efficacy and influence the side-effect profile are delineated and summarized at the molecular level. Those features which most remarkably enhance antimicrobial effectiveness are: a halogen (F or Cl) at the 8-position which improves oral absorption and activity against anaerobes; an alkylated pyrrolidine or piperazine at C7 which increases serum half-life and potency vs Gram-positive bacteria; and a cyclopropyl group at N1 and an amino substituent at C5, both of which improve overall potency. Some side-effects of the quinolones are class effects, and cannot be modulated by molecular variation. These include gastrointestinal irritation and arthropathy. Several other potential side-effects are directly influenced by structural modification. For example, CNS effects and drug interactions with theophylline and NSAIDs are strongly influenced by the C7 substituent with simple pyrrolidines and piperazines the worst actors. Increasing steric bulk through alkylation ameliorates these effects. Phototoxicity is determined by the nature of the 8-position substituent with halogen causing the greatest photo reaction while hydrogen and methoxy show little light induced toxicity. Genetic toxicity is controlled in additive fashion by the choice of groups at the 1, 7 and 8 positions. From the analysis, those groups which mutually improve efficacy while reducing side-effects are identified. In addition, preclinical models for determining potential side-effects are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase
Robicsek, A., Strahilevitz, J., Jacoby, G. A., Macielag, M., Abbanat, D., Hye Park, C., Bush, K., & Hooper, D. C. (2006) · Nature Medicine · doi:10.1038/nm1347 · Cited by 1,013
Pham, T. D. M., Ziora, Z. M., & Blaskovich, M. A. T. (2019) · MedChemComm · doi:10.1039/c9md00120d · Cited by 785
Bacterial Topoisomerase Inhibitors: Quinolone and Pyridone Antibacterial Agents
Mitscher, L. A. (2005) · Chemical Reviews · doi:10.1021/cr030101q · Cited by 781
The fluoroquinolone antibacterials: past, present and future perspectives
Appelbaum, P. C., & Hunter, P. A. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00192-8 · Cited by 629
Drugs: A review of promising novel corrosion inhibitors
Gece, G. (2011) · Corrosion Science · doi:10.1016/j.corsci.2011.08.006 · Cited by 565
The quinolones: decades of development and use
Emmerson, A. M. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg208 · Cited by 531
The Quinolones: Past, Present, and Future
Andriole, V. T. (2005) · Clinical Infectious Diseases · doi:10.1086/428051 · Cited by 428
Bhatt, S., & Chatterjee, S. (2022) · Environmental Pollution · doi:10.1016/j.envpol.2022.120440 · Cited by 428
Antimicrobial Safety: Focus on Fluoroquinolones
Owens, R. C., & Ambrose, P. G. (2005) · Clinical Infectious Diseases · doi:10.1086/428055 · Cited by 415
Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance
Bush, N. G., Diez-Santos, I., Abbott, L. R., & Maxwell, A. (2020) · Molecules · doi:10.3390/molecules25235662 · Cited by 413
Acridine--a neglected antibacterial chromophore
Wainwright, M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.1.1 · Cited by 374
Optical control of antibacterial activity
Velema, W. A., van der Berg, J. P., Hansen, M. J., Szymanski, W., Driessen, A. J. M., & Feringa, B. L. (2013) · Nature Chemistry · doi:10.1038/nchem.1750 · Cited by 371
Cyclopropane Derivatives and their Diverse Biological Activities
Salaün, J. (2000) · Topics in Current Chemistry · doi:10.1007/3-540-48255-5_1 · Cited by 361
A Critical Review of the Fluoroquinolones: Focus on Respiratory Infections
Zhanel, G. G., Ennis, K., Vercaigne, L., Walkty, A., Gin, A. S., Embil, J., Smith, H., & Hoban, D. J. (2002) · Drugs · doi:10.2165/00003495-200262010-00002 · Cited by 344
Van Bambeke, F., Michot, J.-M., Van Eldere, J., & Tulkens, P. M. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01131.x · Cited by 342
Photophysics and photochemistry of fluoroquinolones
Albini, A., & Monti, S. (2003) · Chemical Society Reviews · doi:10.1039/b209220b · Cited by 329
Jiang, C., Ji, Y., Shi, Y., Chen, J., & Cai, T. (2016) · Water Research · doi:10.1016/j.watres.2016.10.025 · Cited by 325
Quinolone generations: natural history or natural selection?
Ball, P. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/oxfordjournals.jac.a020889 · Cited by 302
Kang, J., Wang, L., Chen, X.-L., Triggle, D. J., & Rampe, D. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12364-4 · Cited by 282
Drug-Induced Photosensitivity—An Update: Culprit Drugs, Prevention and Management
Blakely, K. M., Drucker, A. M., & Rosen, C. F. (2019) · Drug Safety · doi:10.1007/s40264-019-00806-5 · Cited by 122
Metadata
- Authors
- Domagala, J. M.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 1994
- Volume
- 33
- Issue
- 4
- Pages
- 685-706
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2099650842
- Cited by
- 681
- References
- 0
- FWCI
- 18.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.